Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Nicotinamide Phosphoribosyltransferase pipeline drugs market research report outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects.
Visfatin Pipeline Drugs Market by Key Therapy Areas
The key therapy areas in the Visfatin pipeline drugs market are oncology, infectious disease, toxicology, cardiovascular, central nervous system, gastrointestinal, immunology, and respiratory.
Visfatin Pipeline Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanism of Actions in the Visfatin Pipeline Drugs Market
The key mechanism of actions of the Visfatin pipeline drugs market are Nicotinamide Phosphoribosyltransferase Inhibitor and Nicotinamide Phosphoribosyltransferase Activator.
Visfatin Pipeline Drugs Market, by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Visfatin Pipeline Drugs Market
The key routes of administration in the Visfatin pipeline drugs market are oral and intravenous.
Visfatin Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Visfatin Pipeline Drugs Market
The key molecule types in the Visfatin pipeline drugs market are small molecule and monoclonal antibody.
Visfatin Pipeline Drugs Market, by Molecule Types
For more molecule types insights, download a free report sample
Key Companies in the Visfatin Pipeline Drugs Market
The key companies in the Visfatin pipeline drugs market are AbbVie Inc, Aqualung Therapeutics Corp, Aurigene Discovery Technologies Ltd, Calico Life Sciences LLC, Eli Lilly and Co, Genentech USA Inc, Karyopharm Therapeutics Inc, OncoTartis Inc, Remedy Plan Inc, Tianjin Hemay Pharmaceutical Co Ltd, and Valo Health LLC.
Visfatin Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Nicotinamide Phosphoribosyltransferase Pipeline Drugs Market Report Overview
Key Therapy Areas | Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System, Gastrointestinal, Immunology, and Respiratory |
Key Mechanism of Actions | Nicotinamide Phosphoribosyltransferase Inhibitor and Nicotinamide Phosphoribosyltransferase Activator |
Key Routes of Administration | Oral and Intravenous |
Key Molecule Types | Small Molecule and Monoclonal Antibody |
Key Companies | AbbVie Inc, Aqualung Therapeutics Corp, Aurigene Discovery Technologies Ltd, Calico Life Sciences LLC, Eli Lilly and Co, Genentech USA Inc, Karyopharm Therapeutics Inc, OncoTartis Inc, Remedy Plan Inc, Tianjin Hemay Pharmaceutical Co Ltd, and Valo Health LLC |
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12).
- Reviews of targeted therapeutics for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) therapeutics and enlists all their major and minor projects.
- Assessment of Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics.
Reasons to Buy
- Gain strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Aqualung Therapeutics Corp
Aurigene Discovery Technologies Ltd
Calico Life Sciences LLC
Eli Lilly and Co
Genentech USA Inc
Karyopharm Therapeutics Inc
OncoTartis Inc
Remedy Plan Inc
Tianjin Hemay Pharmaceutical Co Ltd
Valo Health LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the Visfatin pipeline drugs market?
The key therapy areas in the Visfatin pipeline drugs market are oncology, infectious disease, toxicology, cardiovascular, central nervous system, gastrointestinal, immunology, and respiratory.
-
What are the key mechanism of actions in the Visfatin pipeline drugs market?
The mechanism of actions in the Visfatin pipeline drugs market are Nicotinamide Phosphoribosyltransferase Inhibitor and Nicotinamide Phosphoribosyltransferase Activator.
-
What are the key routes of administration in the Visfatin pipeline drugs market?
The routes of administration in the Visfatin pipeline drugs market are oral and intravenous.
-
What are the key molecule types in the Visfatin pipeline drugs market?
The key molecule type in the Visfatin pipeline drugs market is small molecule and monoclonal antibody.
-
Which are the key companies in the Visfatin pipeline drugs market?
The key companies in the Visfatin pipeline drugs market are AbbVie Inc, Aqualung Therapeutics Corp, Aurigene Discovery Technologies Ltd, Calico Life Sciences LLC, Eli Lilly and Co, Genentech USA Inc, Karyopharm Therapeutics Inc, OncoTartis Inc, Remedy Plan Inc, Tianjin Hemay Pharmaceutical Co Ltd, and Valo Health LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.